Eagle Pharmaceuticals (EGRX) Stock Rating Upgraded by BidaskClub

Eagle Pharmaceuticals (NASDAQ:EGRX) was upgraded by equities researchers at BidaskClub from a “buy” rating to a “strong-buy” rating in a research report issued on Saturday.

A number of other analysts also recently commented on EGRX. Piper Jaffray Companies reissued a “buy” rating and set a $79.00 price objective on shares of Eagle Pharmaceuticals in a report on Tuesday, January 30th. ValuEngine downgraded shares of Eagle Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, February 2nd. Mizuho reissued a “sell” rating and set a $37.00 price objective on shares of Eagle Pharmaceuticals in a report on Monday, February 26th. Royal Bank of Canada set a $71.00 price objective on shares of Eagle Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, February 26th. Finally, Zacks Investment Research downgraded shares of Eagle Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Thursday, March 1st. Two analysts have rated the stock with a sell rating, one has assigned a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $68.00.

EGRX stock opened at $65.36 on Friday. The stock has a market cap of $969.62 million, a P/E ratio of 19.39 and a beta of 1.39. Eagle Pharmaceuticals has a 52 week low of $45.05 and a 52 week high of $84.20. The company has a current ratio of 5.87, a quick ratio of 5.66 and a debt-to-equity ratio of 0.23.



Eagle Pharmaceuticals (NASDAQ:EGRX) last released its quarterly earnings data on Thursday, May 10th. The specialty pharmaceutical company reported $0.53 EPS for the quarter, missing analysts’ consensus estimates of $0.68 by ($0.15). The company had revenue of $46.60 million for the quarter, compared to analysts’ expectations of $48.88 million. Eagle Pharmaceuticals had a return on equity of 21.89% and a net margin of 15.32%. The firm’s quarterly revenue was down 39.3% on a year-over-year basis. During the same period in the prior year, the firm posted $1.42 EPS. equities analysts predict that Eagle Pharmaceuticals will post 1.92 earnings per share for the current year.

In other Eagle Pharmaceuticals news, Director Sander A. Flaum sold 2,340 shares of the company’s stock in a transaction dated Tuesday, March 6th. The shares were sold at an average price of $53.94, for a total value of $126,219.60. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 19.50% of the stock is owned by corporate insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in the business. BlackRock Inc. lifted its holdings in shares of Eagle Pharmaceuticals by 1.3% in the first quarter. BlackRock Inc. now owns 1,248,803 shares of the specialty pharmaceutical company’s stock valued at $65,800,000 after purchasing an additional 16,405 shares in the last quarter. Park West Asset Management LLC lifted its holdings in shares of Eagle Pharmaceuticals by 1.4% in the first quarter. Park West Asset Management LLC now owns 1,051,274 shares of the specialty pharmaceutical company’s stock valued at $55,392,000 after purchasing an additional 15,000 shares in the last quarter. Victory Capital Management Inc. lifted its holdings in shares of Eagle Pharmaceuticals by 7.4% in the fourth quarter. Victory Capital Management Inc. now owns 1,050,167 shares of the specialty pharmaceutical company’s stock valued at $56,101,000 after purchasing an additional 72,217 shares in the last quarter. Iridian Asset Management LLC CT lifted its holdings in shares of Eagle Pharmaceuticals by 10.7% in the fourth quarter. Iridian Asset Management LLC CT now owns 901,697 shares of the specialty pharmaceutical company’s stock valued at $48,169,000 after purchasing an additional 87,483 shares in the last quarter. Finally, LSV Asset Management lifted its holdings in shares of Eagle Pharmaceuticals by 17.1% in the first quarter. LSV Asset Management now owns 859,142 shares of the specialty pharmaceutical company’s stock valued at $45,268,000 after purchasing an additional 125,320 shares in the last quarter.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers argatroban for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; non-alcohol docetaxel injection, a chemotherapeutic agent for breast, non-small cell lung, prostate, head, and neck cancers/gastric adenocarcinoma; and Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL).

Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply